Claims
- 1. An isolated or recombinant polypeptide that:
a) specifically binds polyclonal antibodies generated against at least a 12 consecutive amino acid segment of SEQ ID NO: 2 or 4; and b) comprises at least one sequence selected from:
i) GENSGVK; EDWEKD; CCLEDPA; FVHTSR; KKFSIHD; VLVLDS; NLIAVP; FFALAS; SSASAEK; SLILLGV; FCLYCDK; PSLQLK; KLMKLAAQ; FIFYRAQ; SRNMLES; WFICTS; EPVGVT; or FSFQPVC (see SEQ ID NO: 2); or ii) FVHTSP; SPILLGV; or SWNMLES (see SEQ ID NO: 4).
- 2. The polypeptide of claim 1:a) wherein said polypeptide comprises a plurality of said sequences selected from said groups in section b); b) which specifically binds to polyclonal antibodies generated against an immunogen selected from SEQ ID NO: 2 or 4; or c) wherein said 12 consecutive amino acid segment is selected from: GVKMGSEDWEKD; AGSPLEPGPSLP; SRKVKSLNPKKF; HDQDHKVLVLDS; NLIAVPDKNYIR; FALASSLSSASA; GQSHPSLQLKKE; MKLAAQKESARR; FYRAQVGSRNML; TSCNCNEPVGVT; FENRKHIEFSFQ; or PVCKAEMSPSEV (see SEQ ID NO: 2); or AVSPLEPGPSLP; SPKVKNLNPKKF; or FYRAQVGSWNML (see SEQ ID NO: 4).
- 3. The polypeptide of claim 2, wherein said polypeptide:
i) comprises a mature protein; ii) lacks a post-translational modification; iii) is from a primate, including a human; iv) is a natural allelic variant of IL-1ζ; v) has a length at least about 30 amino acids; vi) exhibits at least two non-overlapping epitopes that are specific for a primate IL-1ζ; vii) exhibits a sequence identity over a length of at least about 20 amino acids to SEQ ID NO: 2 or 4; viii) is not glycosylated; ix) has a molecular weight of at least 10 kD with natural glycosylation; x) is a synthetic polypeptide; xi) is attached to a solid substrate; xii) is conjugated to another chemical moiety; xiii) is a 5-fold or less substitution from natural sequence; or xiv) is a deletion or insertion variant from a natural sequence.
- 4. A composition of matter comprising:
a) a sterile polypeptide of claim 2;b) said sterile polypeptide of claim 2 and a carrier, wherein said carrier is:
i) an aqueous compound, including water, saline, and/or buffer; and/or ii) formulated for oral, rectal, nasal, topical, or parenteral administration.
- 5. A fusion protein having a polypeptide sequence of claim 2 further comprising:
a) a mature polypeptide of claim 2;b) a detection or purification tag, including a FLAG, His6, or Ig sequence; or c) sequence of another cytokine or chemokine.
- 6. A-kit comprising a polypeptide of claim 2, and:
a) a compartment comprising said polypeptide; and/or b) instructions for use or disposal of reagents in said kit.
- 7. A binding compound comprising an antigen binding site from an antibody, which specifically binds to a mature polypeptide of claim 2, wherein:
a) said mature polypeptide is a primate IL-1ζ; b) said binding compound is an Fv, Fab, or Fab2 fragment; c) said binding compound is conjugated to another chemical moiety; or d) said antibody:
i) is raised against a 12 consecutive amino acid segment of SEQ ID NO: 2 or 4; ii) is raised against a mature IL-1ζ; iii) is raised to a purified primate IL-1ζ; iv) is immunoselected; v) is a polyclonal antibody; vi) binds to a denatured IL-1ζ; vii) exhibits a Kd to antigen of at least 30 μM; viii) is attached to a solid substrate, including a bead or plastic membrane; ix) is in a sterile composition; or x) is detectably labeled, including a radioactive or fluorescent label.
- 8. A kit comprising said binding compound of claim 7, and:
a) a compartment comprising said binding compound; and/or b) instructions for use or disposal of reagents in said kit.
- 9. A composition comprising:
a) a sterile binding compound of claim 7, or b) said binding compound of claim 7 and a carrier, wherein said carrier is:
i) an aqueous compound, including water, saline, and/or buffer; and/or ii) formulated for oral, rectal, nasal, topical, or parenteral administration.
- 10. An isolated or recombinant nucleic acid encoding a polypeptide of claim 2, wherein:
a) said polypeptide of claim 2 is a primate IL-1ζ; or b) said nucleic acid:
i) encodes an antigenic peptide sequence of SEQ ID NO: 2 or 4; ii) encodes a plurality of antigenic peptide sequences of SEQ ID NO: 2 or 4; iii) exhibits at least about 80% identity to a natural cDNA encoding said segment; iv) is an expression vector; v) further comprises an origin of replication; vi) is from a natural source; vii) comprises a detectable label; viii) comprises synthetic nucleotide sequence; ix) is less than 6 kb, preferably less than 3 kb; x) is from a rodent; xi) comprises a natural full length coding sequence; xii) is a hybridization probe for a gene encoding said IL-1ζ; or xiii) is a PCR primer, PCR product, or mutagenesis primer; or xiv) encodes an IL-1ζ polypeptide.
- 11. A cell, transformed with said nucleic acid of claim 10.
- 12. The cell of claim 11, wherein said cell is:
a) a prokaryotic cell; b) a eukaryotic cell; c) a bacterial cell; d) a yeast cell; e) an insect cell; f) a mammalian cell; g) a mouse cell; h) a primate cell; or i) a human cell.
- 13. A kit comprising said nucleic acid of claim 10, and:
a) a compartment further comprising a primate IL-1ζ polypeptide; and/or b) instructions for use or disposal of reagents in said kit.
- 14. An isolated or recombinant nucleic acid that hybridizes under wash conditions of 30° C. and less than 2M salt to SEQ ID NO: 1.
- 15. The nucleic acid of claim 14, wherein:
a) said wash condition is at 45° C. and/or 500 mM salt; or b) said nucleic acid encodes at least 12 contiguous amino acids of SEQ ID NO: 2 or 4.
- 16. The nucleic acid of claim 15, wherein:
a) said wash condition is at 55° C. and/or 150 mM salt; or b) said nucleic acid encodes at least 17 contiguous amino acids of SEQ ID NO: 2 or 4.
- 17. A method of modulating a cell involved in an inflammatory response comprising contacting said cell with an agonist or antagonist of a primate IL-1ζ polypeptide of claim 1.
- 18. The method of claim 17, wherein:
a) said contacting is in combination with an agonist or antagonist of IL-1α, IL-1RA, IL-1β, IL-1γ, IL-1δ, IL-1ε, IL-2, and/or IL-12; b) said contacting is with an antagonist, including binding composition comprising an antibody binding site which specifically binds an IL-1ζ; or c) said modulating is regulation of IFN-γ production.
- 19. A binding compound comprising an antigen binding portion from an antibody, which specifically binds to a primate protein of claim 1, wherein:
a) said protein is a human protein; b) said binding compound is an Fv, Fab, or Fab2 fragment; c) said binding compound is conjugated to another chemical moiety; or d) said antibody:
i) is raised against a polypeptide sequence of a mature polypeptide comprising at least 12 consecutive amino acids of SEQ ID NO: 2 or 4; ii) is raised against a mature primate IL-1ζ; iii) is raised to a purified primate IL-1ζ; iv) is immunoselected; v) is a polyclonal antibody; vi) binds to a denatured primate IL-1ζ; vii) exhibits a Kd to antigen of at least 30 μM; viii) is attached to a solid substrate, including a bead or plastic membrane; ix) is in a sterile composition; or x) is detectably labeled, including a radioactive or fluorescent label.
- 20. A method of:
A) making an antibody of claim 19, comprising immunizing an immune system with an immunogenic amount of:
a) a primate IL-1ζ polypeptide; or b) a peptide sequence comprising at least 12 consecutive amino acids of SEQ ID NO: 2 or 4; thereby causing said antibody to be produced; or B) producing an antigen:antibody complex, comprising contacting a primate IL-1ζ polypeptide with an antibody of claim 19 thereby allowing said complex to form.
Parent Case Info
[0001] This filing is a conversion from U.S. Provisional Patent Application U.S. Ser. No. 60/100,948, filed Sep. 18, 1998, to a U.S. Utility Patent Application.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60100948 |
Sep 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09398412 |
Sep 1999 |
US |
Child |
10695195 |
Oct 2003 |
US |